What is the difference between Cagrilintide and Retatrutide?

Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Retatrutide is classified as: Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide). Cagrilintide is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine.

Is Cagrilintide or Retatrutide approved?

Cagrilintide is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Cagrilintide and Retatrutide?

Peptide Science Daily tracks 42 registered clinical trials for Cagrilintide (evidence grade B) and 34 for Retatrutide (evidence grade B).

Compound comparison

Cagrilintide vs Retatrutide

This page sets Cagrilintide and Retatrutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Cagrilintide
Long-acting amylin (and calcitonin) receptor agonist / amylin analogue
Retatrutide
Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
Mechanism: Cagrilintide
In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.
Retatrutide
In plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy.
United States (FDA): Cagrilintide
Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.
Retatrutide
Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025.
European Union (EMA): Cagrilintide
Not authorized; investigational, no marketing authorization.
Retatrutide
Not authorized; investigational, no marketing authorization.
Australia (TGA): Cagrilintide
Not entered on the ARTG; investigational only and not approved for supply.
Retatrutide
Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
WADA: Cagrilintide
Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.
Retatrutide
Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited.
Evidence grade: Cagrilintide
B
Retatrutide
B
Tracked clinical trials: Cagrilintide
42
Retatrutide
34
Full profile: Cagrilintide
Cagrilintide profile
Retatrutide
Retatrutide profile

Comparison of Cagrilintide and Retatrutide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Cagrilintide	Retatrutide
Class	Long-acting amylin (and calcitonin) receptor agonist / amylin analogue	Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
Mechanism	In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.	In plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy.
United States (FDA)	Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.	Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025.
European Union (EMA)	Not authorized; investigational, no marketing authorization.	Not authorized; investigational, no marketing authorization.
Australia (TGA)	Not entered on the ARTG; investigational only and not approved for supply.	Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
WADA	Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.	Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited.
Evidence grade	B	B
Tracked clinical trials	42	34
Full profile	Cagrilintide profile	Retatrutide profile

Common questions

What is the difference between Cagrilintide and Retatrutide?: Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Retatrutide is classified as: Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide). Cagrilintide is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine.
Is Cagrilintide or Retatrutide approved?: Cagrilintide is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Cagrilintide and Retatrutide?: Peptide Science Daily tracks 42 registered clinical trials for Cagrilintide (evidence grade B) and 34 for Retatrutide (evidence grade B).